Noteworthy Wednesday Option Activity: CPRI, AXP, MLYS

Significant options activity was recorded in American Express (AXP) and Mineralys Therapeutics (MLYS). AXP saw 14,568 contracts traded (~1.46M underlying shares, ~57.5% of its 1‑month ADV of 2.5M shares), led by 2,599 contracts in the $345 put expiring Dec 5, 2025 (~259,900 shares). MLYS logged 10,519 contracts (~1.05M underlying shares, ~56.2% of its 1‑month ADV of 1.9M), highlighted by 3,500 contracts in the $30 put expiring Mar 20, 2026 (~350,000 shares). The concentrated put flows suggest notable bearish positioning in both names that may warrant monitoring by trading desks and risk teams.

Analysis

Market structure: The outsized put flows in AXP (14,568 contracts ≈1.5M shares, 57.5% of ADV) and MLYS (10,519 contracts ≈1.1M shares, 56.2% of ADV) benefit options sellers/market‑makers via elevated IV and hedging fees, while directional put buyers (speculative shorts or institutional hedgers) signal concentrated downside interest. Large single‑strike concentration (AXP $345 Dec‑5‑2025; MLYS $30 Mar‑20‑2026) implies idiosyncratic bets or event hedges that can force delta‑hedge equity flows equal to hundreds of thousands of shares, temporarily pressuring or supporting the underlying.

Risk assessment: Near term (days) expect elevated implied volatility and asymmetric order flow; short term (weeks–months) delta‑hedging may amplify moves into earnings/data windows; long term (quarters) fundamentals (AXP payments volumes, MLYS clinical readouts) dominate. Tail risks include an adverse AXP regulatory or credit shock and a clinical failure or buyout for MLYS; monitor open interest and block reporting as a single counterparty could flip market direction quickly.

Trade implications: Prefer defined‑risk structures over naked exposure: for AXP use long put spreads to hedge concentrated equity exposure; for MLYS treat the move as a volatility sell candidate only after IV tail recedes — otherwise buy protection if you're long biotech. Relative trades: rotate 1–2% from high‑IV biotech into cash‑flowing card/network names (AXP, V, MA) for 4–12 week horizon and opportunistically sell short‑dated premium when IV > 30% above 30‑day realized.

Contrarian angles: Consensus assumes directional bearishness; the flow could be institutional macro hedges (not fundamental shorting), meaning downside may be already priced and IV overstated. Historically similar put spikes have mean‑reverted within 2–6 weeks absent idiosyncratic news; watch for pinning around the highlighted strikes and for buyback/covering squeezes that could invert the trade.

Key Decisions for Investors

• AXP: Establish a 1.5–2.0% long equity position within 5 trading days and hedge 50% of that position with a defined Dec‑05‑2025 $345/$320 put spread (protects vs ~7–10% downside) to limit cost and preserve upside exposure.
• MLYS: Allocate a 0.5% notional (portfolio %) to buy the Mar‑20‑2026 $30/$20 put spread as a defined‑risk hedge/speculation; cap total biotech exposure reduction to 1–2% if spread cost >0.6% portfolio or IV>50%.
• Volatility harvesting: If AXP Dec‑2025 put IV rises >25% above 30‑day realized vol, sell 30–45 day 1.5% OTM put credit spreads sized to collect premium equal to ≤0.5% portfolio while keeping defined max loss.
• Portfolio rotation: Over the next 4–8 weeks reduce high‑IV small‑cap biotech exposure by 1–2% and redeploy into cash‑generative payments/financials (AXP, V, MA) for a defensive carry tilt while monitoring upcoming AXP earnings and MLYS catalyst dates.